Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: CT-322
Drug: Bevacizumab
Drug: Bevacizumab placebo (ie saline solution)

First Posted Date: 2009-02-25

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 255

Registration Number: NCT00850577

Locations: 🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸
Clintell, Inc., Skokie, Illinois, United States
🇺🇸
North Canton Medical Clinic Center, Canton, Ohio, United States

and more 19 locations

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Phase 1

Completed

Conditions: Locally Advanced, Metastatic Solid Tumors

Interventions: Drug: MK-2206
Drug: docetaxel
Drug: carboplatin
Drug: erlotinib
Drug: corticosteroid
Drug: paclitaxel

First Posted Date: 2009-02-20

Last Posted Date: 2019-11-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 77

Registration Number: NCT00848718

A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel
Drug: Gemcitabine

First Posted Date: 2009-02-18

Last Posted Date: 2014-07-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 90

Registration Number: NCT00846027

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel

First Posted Date: 2009-02-06

Last Posted Date: 2013-09-17

Lead Sponsor: Warwick Medical School

Target Recruit Count: 88

Registration Number: NCT00838656

Locations: 🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧
Good Hope Hospital, Birmingham, England, United Kingdom

and more 1 locations

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: E7080
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-01-30

Last Posted Date: 2015-04-30

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT00832819

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2009-01-26

Last Posted Date: 2013-11-06

Lead Sponsor: Accelerated Community Oncology Research Network

Target Recruit Count: 601

Registration Number: NCT00828841

Locations: 🇺🇸
Family Medicine of Vincennes, Vincennes, Indiana, United States

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Biological: Tecemotide
Drug: carboplatin
Drug: cyclophosphamide
Drug: paclitaxel
Radiation: radiotherapy

First Posted Date: 2009-01-23

Last Posted Date: 2023-07-07

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 70

Registration Number: NCT00828009

Locations: 🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸
Hematology Oncology Associates - Skokie, Skokie, Illinois, United States

and more 85 locations